Conferences

Our Conferences articles contain the latest coverage of medical advancements from recent academic conferences.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

Recent Articles

Comparing CRS and ICANS Among Bispecific Antibodies

February 10, 2025

Explore side effects of bispecific antibodies for myeloma and B-cell lymphoma treatment, comparing brands on CRS, ICANS, and IEC-HS severity.

Understanding Barriers to CAR T-Cell Therapy for Blood Cancer Patients

January 31, 2025

If blood cancer patients are referred to receive CAR T-cell therapy, what barriers are keeping them from receiving it? Learn answers in this article.

Is There Hope for Trispecific Antibodies in Myeloma Care?

January 23, 2025

Learn how trispecific antibody treatments have been faring for myeloma patients. While some have been unsuccessful, researchers continually improve the product.

A Better Understanding of Black Myeloma Biology (And How Racism Plays a Role in Outcomes)

January 22, 2025

Learn how the understanding of Black myeloma biology continues to advance (and how much is related to racism.)

Promising Results from Arlo-cel CAR T in Myeloma

January 09, 2025

Learn about a. new CAR T product, arlo-cel, that targets GPRC5D on multiple myeloma cells. The early results are extremely encouraging.

Barriers to Proper Genetic Testing? Understanding FISH Access

January 08, 2025

Learn what's keeping people from truly understanding their myeloma genetics as many experience barriers to the incredibly helpful FISH test.

Addressing Disparities in Multiple Myeloma Care: What It Means for Patients

January 07, 2025

Learn what Black myeloma patients, caregivers and advocates suggest to solve some of the healthcare disparities that exist today.

CAR T-Cell Therapy: Long-Term Side Effects and Patient Outcomes from ASH 2024

December 23, 2024

CAR T-cell therapy's long-term effects, patient-reported outcomes, and infection management strategies from ASH 2024. Expert insights from leading oncologists.

Studying Quality of Life With and Without Elotuzumab in Newly Diagnosed Myeloma

December 18, 2024

Learn how newly diagnosed myeloma patients felt their quality of life was impacted both on and off regimens with elotuzumab.

What Can Be Done to Predict Optimal CAR-T Responses?

December 17, 2024

Learn how previous therapies, including BCMA-directed treatment and stem cell transplants, can affect CAR T cell therapy outcomes in multiple myeloma.